292 related articles for article (PubMed ID: 34323406)
21. The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients.
Zhuo M; Chen H; Zhang T; Yang X; Zhong J; Wang Y; An T; Wu M; Wang Z; Huang J; Zhao J
Cancer Biomark; 2018; 22(3):467-476. PubMed ID: 29758930
[TBL] [Abstract][Full Text] [Related]
22. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
[TBL] [Abstract][Full Text] [Related]
24. Circulating myeloid-derived suppressors cells correlate with clinicopathological characteristics and outcomes undergoing neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Wen T; Su C; Cheng X; Wang Y; Ma T; Bai Z; Zhang H; Liu Z
Clin Transl Oncol; 2022 Jun; 24(6):1184-1194. PubMed ID: 34988921
[TBL] [Abstract][Full Text] [Related]
25. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.
Rolfo C; Caglevic C; Santarpia M; Araujo A; Giovannetti E; Gallardo CD; Pauwels P; Mahave M
Adv Exp Med Biol; 2017; 995():97-125. PubMed ID: 28321814
[TBL] [Abstract][Full Text] [Related]
27. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.
Parra ER; Villalobos P; Behrens C; Jiang M; Pataer A; Swisher SG; William WN; Zhang J; Lee J; Cascone T; Heymach JV; Forget MA; Haymaker C; Bernatchez C; Kalhor N; Weissferdt A; Moran C; Zhang J; Vaporciyan A; Gibbons DL; Sepesi B; Wistuba II
J Immunother Cancer; 2018 Jun; 6(1):48. PubMed ID: 29871672
[TBL] [Abstract][Full Text] [Related]
28. Survivin mRNA Level in Blood Predict the Efficacy of Neoadjuvant Chemotherapy in Patients with Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hu YM; Li J; Yu LC; Shi SB; Du YJ; Wu JN; Shi WL
Pathol Oncol Res; 2015 Apr; 21(2):257-65. PubMed ID: 24980156
[TBL] [Abstract][Full Text] [Related]
29.
Yaegashi LB; Baldavira CM; Prieto TG; Machado-Rugolo J; Velosa APP; da Silveira LKR; Assato A; Ab'Saber AM; Falzoni R; Takagaki T; Silva PL; Teodoro WR; Capelozzi VL
Front Immunol; 2021; 12():714230. PubMed ID: 34484217
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Forde PM; Chaft JE; Smith KN; Anagnostou V; Cottrell TR; Hellmann MD; Zahurak M; Yang SC; Jones DR; Broderick S; Battafarano RJ; Velez MJ; Rekhtman N; Olah Z; Naidoo J; Marrone KA; Verde F; Guo H; Zhang J; Caushi JX; Chan HY; Sidhom JW; Scharpf RB; White J; Gabrielson E; Wang H; Rosner GL; Rusch V; Wolchok JD; Merghoub T; Taube JM; Velculescu VE; Topalian SL; Brahmer JR; Pardoll DM
N Engl J Med; 2018 May; 378(21):1976-1986. PubMed ID: 29658848
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.
Pircher A; Gamerith G; Amann A; Reinold S; Popper H; Gächter A; Pall G; Wöll E; Jamnig H; Gastl G; Wolf AM; Hilbe W; Wolf D
Lung Cancer; 2014 Jul; 85(1):81-7. PubMed ID: 24780112
[TBL] [Abstract][Full Text] [Related]
32. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109
[TBL] [Abstract][Full Text] [Related]
33. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
Zheng H; Liu X; Zhang J; Rice SJ; Wagman M; Kong Y; Zhu L; Zhu J; Joshi M; Belani CP
Oncotarget; 2016 Aug; 7(35):56233-56240. PubMed ID: 27191652
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of combined pathological responses in primary tumor and lymph nodes following neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Huang S; Wu J; Li S; Li X; Zeng R; Tang Y; Tang J; Ben X; Zhang D; Xie L; Zhou H; Chen G; Wang S; Gao Z; Wu H; Chen R; Xu F; Qiao G
Lung Cancer; 2023 Dec; 186():107401. PubMed ID: 37844351
[TBL] [Abstract][Full Text] [Related]
35. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
36. Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study.
Hu M; Li X; Lin H; Lu B; Wang Q; Tong L; Li H; Che N; Hung S; Han Y; Shi K; Li C; Zhang H; Liu Z; Zhang T
Int J Surg; 2024 Apr; 110(4):2275-2287. PubMed ID: 38265431
[TBL] [Abstract][Full Text] [Related]
37. Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC).
Hui Z; Zhang J; Ren Y; Li X; Yan C; Yu W; Wang T; Xiao S; Chen Y; Zhang R; Wei F; You J; Ren X
Cell Death Dis; 2022 Jul; 13(7):607. PubMed ID: 35831283
[TBL] [Abstract][Full Text] [Related]
38. Plasma D-Dimer Level Correlates with Age, Metastasis, Recurrence, Tumor-Node-Metastasis Classification (TNM), and Treatment of Non-Small-Cell Lung Cancer (NSCLC) Patients.
Guo J; Gao Y; Gong Z; Dong P; Mao Y; Li F; Rong J; Zhang J; Zhou Y; Feng H; Guo H; Gu L; An M; Wen K; Zhang J
Biomed Res Int; 2021; 2021():9623571. PubMed ID: 34712737
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers of response to immunotherapy in early stage non-small cell lung cancer.
Roulleaux Dugage M; Albarrán-Artahona V; Laguna JC; Chaput N; Vignot S; Besse B; Mezquita L; Auclin E
Eur J Cancer; 2023 May; 184():179-196. PubMed ID: 36963241
[TBL] [Abstract][Full Text] [Related]
40. Tumor microenvironment(TME) and single-source dual-energy CT(ssDECT) on assessment of inconformity between RECIST1.1 and pathological remission in neoadjuvant immunotherapy of NSCLC.
Sun C; Ma X; Meng F; Chen X; Wang X; Sun W; Xu Y; He H; Zhang H; Ma K
Neoplasia; 2024 Apr; 50():100977. PubMed ID: 38354688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
